Cerivastatin and the dissemination of adverse event information.
Weaver
S Jay
SJ
Drug Information Practice, University of Florida Drug Information, Gainesville 32610-0486, USA. weavesj@shands.ufl.edu
Doering
Paul L
PL
D016907:Adverse Drug Reaction Reporting Systems / Q000458:organization & administration / Q000592:standards; D000075202:Contraindications; D016208:Databases, Factual; D017277:Drug Approval; D004348:Drug Labeling; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects*; D010604:Pharmacy / Q000379:methods / Q000592:standards; D011725:Pyridines / Q000009:adverse effects*; D018570:Risk Assessment; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011725:Pyridines; C086276:cerivastatin